Walvax Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
Walvax Biotechnology has a total shareholder equity of CN¥11.7B and total debt of CN¥712.0M, which brings its debt-to-equity ratio to 6.1%. Its total assets and total liabilities are CN¥15.0B and CN¥3.3B respectively. Walvax Biotechnology's EBIT is CN¥348.4M making its interest coverage ratio -5.5. It has cash and short-term investments of CN¥3.6B.
Key information
6.1%
Debt to equity ratio
CN¥711.96m
Debt
| Interest coverage ratio | -5.5x |
| Cash | CN¥3.62b |
| Equity | CN¥11.73b |
| Total liabilities | CN¥3.27b |
| Total assets | CN¥15.00b |
Recent financial health updates
We Think Walvax Biotechnology (SZSE:300142) Can Stay On Top Of Its Debt
Nov 25
Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Jun 19Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Mar 01Recent updates
We Think Walvax Biotechnology (SZSE:300142) Can Stay On Top Of Its Debt
Nov 25Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S
Sep 24Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Jun 19Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares
May 23There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings
Apr 07Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 02Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Mar 01Financial Position Analysis
Short Term Liabilities: 300142's short term assets (CN¥7.4B) exceed its short term liabilities (CN¥2.4B).
Long Term Liabilities: 300142's short term assets (CN¥7.4B) exceed its long term liabilities (CN¥883.7M).
Debt to Equity History and Analysis
Debt Level: 300142 has more cash than its total debt.
Reducing Debt: 300142's debt to equity ratio has increased from 0% to 6.1% over the past 5 years.
Debt Coverage: 300142's debt is well covered by operating cash flow (116.9%).
Interest Coverage: 300142 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 11:34 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Walvax Biotechnology Co., Ltd. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Tong Zhang | China Merchants Securities Co. Ltd. |
| Ling Bo Tu | China Minzu Securities |